ArticleJournal of contemporary brachytherapy2026
Efficacy of peri-operative high-dose-rate interstitial brachytherapy in keloids: Can we scare the bad scar?
Article in Journal of contemporary brachytherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Keloids arise from dysregulated wound healing, characterized by excessive fibroblast activity and collagen deposition. Despite multiple treatment modalities, recurrence rates after excision remain high. High-dose-rate (HDR) brachytherapy delivers localized radiation, minimizing exposure to surrounding structures. This study evaluated clinical outcomes and dosimetric parameters in patients undergoing surgical excision followed by peri-operative HDR brachytherapy for keloid management at a single institution. Material and methods: In this retrospective analysis, 32 patients treated over the past 6 years who underwent scar excision and immediate peri-operative brachytherapy to a dose of 15 Gy in 3 fractions, were analyzed. Outcomes, including recurrence, acute reactions, delayed wound healing, and late pigmentary or cosmetic changes, were assessed Results: The study comprised 17 males and 15 females (median age, 33 years; range, 21-65 years). Keloid sites included the ear (50%), chest (40.6%), extremities (6.3%), and scapula (3.1%). Median length treated and volume were 3.75 cm and 1.7 cm Conclusions: Surgical excision and immediate peri-operative brachytherapy can be considered in the first occurrence of keloid. Attention should be paid to interval between surgery and radiotherapy (RT) start, and to the dosimetric optimization of RT treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.